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Pharmacological Interactions
The Next Frontier?*
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Medical therapy for coronary artery disease (CAD) has
greatly improved in recent years. It includes drugs aimed at
specific targets within the multifactorial atherothrombotic
process. Patients receive antiplatelet agents, statins,
-blockers, and in selected patients angiotensin-receptor
blockers (1). Although these drugs have specific targets,
their complex mechanism of action remains incompletely
determined. In fact, for most of these drugs, studies have
underlined that beyond the targeted effect there are other
See page 169
unanticipated actions that could have clinical implications.
For example, pleiotropic effects of statins well beyond their
efficacy on low-density lipoprotein cholesterol might be
contributory (2,3). For clopidogrel, which remains the most
commonly used P2Y12-adenosine diphosphate receptor
used in CAD patients, recent studies suggested endothelial
and anti-inflammatory properties beyond blockade of the
P2Y12-adenosine diphosphate receptor on platelets (4,5).
These “off-target” effects of drugs are of potential clinical
interest.
Finally another important question that remains largely
uninvestigated is the interaction between these drugs. In
fact, although studies have focused on the overall clinical
impact, few have addressed the potential interactions be-
tween these drugs and their subsequent clinical impact. This
was recently illustrated by the negative clinical interaction
between clopidogrel and proton pump inhibitors (5). These
critical areas of drug interactions and “off-targeted” effects
require further research. Therefore, Leoncini et al. (6)
should be congratulated for moving this field forward. In
their study in this issue of JACC: Cardiovascular Interven-
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As mentioned in the preceding text, statins are consid-
ered as having biological properties beyond lipid lowering
that participate in their overall clinical benefit (7). Experi-
mental data suggested that 3-hydroxy-3-methyl-glutaryl-
CoA reductase inhibitors have the ability to directly reduce
platelet aggregation (2). Consistently, statins were shown to
significantly decrease thrombus formation and improve the
fibrinolytic profile of patients with and without CAD (3). In
addition, there is evidence suggesting that high-dose statins
have greater “off-target” effects (8). These “off-target” prop-
erties of statins are of obvious potential clinical benefit in
CAD patients. In the present well-controlled and well-
performed study, Leoncini et al. (6) aimed to investigate the
potential synergistic effect between high-dose atorvastatin
and clopidogrel on PR as assessed by the VerifyNow P2Y12.
Clopidogrel is a prodrug, which necessitates biotransfor-
mation in the liver to its active metabolites. Its complex
metabolization is responsible for an inter-individual vari-
ability that might result in the persistence of high on-
treatment platelet reactivity (HTPR) in a significant pro-
portion of patients (9). This biological entity has been fully
studied and is now well-characterized. HTPR is due to
various factors that might intervene alone or in combina-
tion. In part it is related to the presence of loss of function
mutant alleles, including the 2*, encoding the 2C19 cyto-
chrome that participates in both steps of clopidogrel bioac-
tivation (10). HTPR was shown to translate into an excess
of thrombotic events in patients undergoing PCI, including
stent thrombosis and cardiovascular death (9). Therefore,
several trials have evaluated therapeutic strategies to over-
come HTPR to improve the clinical outcome of patients.
The study by Leoncini et al. has several strengths. It is
prospective, randomized, and has an active control. In
addition the definition of HTPR is consistent with the
published data that correlate with clinical events with a
P2Y12 reaction units 235 by the VerifyNow P2Y12 assay
3). The authors demonstrated that adding high-dose ator-
astatin to clopidogrel had a synergistic effect on PR. In
ddition they found no link between lipid fraction and PR
evel, suggesting that this biological impact of atorvastatin
n PR was independent of its action on cholesterol.
However, there are potential limitations of the present
ork. This study was relatively small. Furthermore, the
linical impact of such findings remains elusive, because this
bservation was made in patients with stable CAD where
R might be less relevant, given the low rate of thrombotic
vents. In addition, the maintenance dose of clopidogrel is
ot consistent with guidelines and clinical practice. This
tudy also did not investigate the potential mechanism of
uch interactions. Does atorvastatin promote PR inhibition
hrough a direct antiplatelet effect as suggested by previous
tudies or through an interaction with clopidogrel metabo-
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181lism? Finally, the relevance of PR testing in elective PCI is
questionable, because recent studies have failed to demon-
strate a clinical benefit of improved PR inhibition in HTPR
patients undergoing PCI for stable CAD (11,12).
However, although the present study has limited clinical
implication, it is important in validating a potential mech-
anism of action of statins and further acknowledges their
pleiotropic effects. In addition it underlines the complex
interplay taking place in atherothrombosis and, most im-
portantly, the interactions between commonly used drugs.
The authors should be congratulated for performing the
present work, which explores both “off-target” effects of
therapy and their interactions.
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